Clinical trial
Study of Dupilumab (REGN668/ SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
To assess the efficacy of multiple dupilumab (REGN668/ SAR231893) dose-regimens, compared to placebo, in adult patients with moderate-to-severe atopic dermatitis (AD).
| Category | Value |
|---|---|
| Study start date | 2013-05-20 |